Effect of atenolol and celiprolol on acetylcholine-induced coronary vasomotion in coronary artery disease

American Journal of Cardiology

Volumn 85, Issue 2, 2000, Pages 172-177

  Burger, Wolfram ^a   Hampel, Christian ^b   Kaltenbach, Martin ^b   Hartmann, Andreas ^a   Herrmann, Manfred ^a   Hoffmann, Josef A ^a   Klepzig, Harald ^b  

^a Klinikum St Georg   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELIPROLOL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PLACEBO;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTERY ENDOTHELIUM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; HEMODYNAMICS; HUMAN; INTRACORONARY INFUSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE;

ACETYLCHOLINE; ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; CELIPROLOL; CORONARY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 0033979925     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00648-7     Document Type: Article

References (29)

1. Vatner S.F., Hintze H.T. Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade. Circ Res. 53:1983;389-400.
2. Milne R.J., Buckley M.M.T. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic and therapeutic efficacy in cardiovascular disease. Drugs. 41:1991;941-969.
3. 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and β-adrenoceptor subtype specific occupancy of celiprolol in healthy man. Eur J Clin Pharm. 44:1993;341-348.
4. Dhein S., Titzer S., Wallstein M., Müller A., Gerwin R., Panzner B., Klaus W. Celiprolol exerts microvascular dilatation by activation of beta 2 adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol. 364:1992;27-31.
5. Ridell J.G., Shanks R.G., Brogden R.N. Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs. 34:1987;438-458.
6. Thulesius O., Gjöres J.E., Berlin E. Vasodilating properties of β-adrenoceptor blockers with intrinsic sympathomimetic activity. Br J Clin Pharm. 13:1982;229S-230S.
7. Gensini G., Dator D., Esente P., Caruso F.S., Solomon T. Comparison of the acute haemodynamic effects of intravenous celiprolol and propanolol in patients with suspected coronary disease. J Cardiovasc Pharm. 8:(suppl 4):1986;83S-85S.
8. Hughes A, Martin G, Goldberg P, Thom S, Sever P. No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo and in vitro. J Cardiovasc Pharm 1987;10:598-592.
9. Heublein B., Modersohn D., Franz N., Panzner B. Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension a double blind comparison with metoprolol . Eur Heart J. 12:1991;617-623.
10. O'Rourke S.T., Vanhoutte P.M. Celiprolol has no direct or indirect relaxing effects in isolated arteries and veins. J Cardiovasc Pharm. 15:1990;831-835.
11. Bonelli J., Magometschnigg D., Hitzenberger G., Kaik G. Hämodynamische Charakterisierung eines neuen Beta-Rezeptorenblockers Celiprolol (ST 1396) in Ruhe und unter Ergometerbelastung verglichen mit Propranolol . Wien klin Wschr. 90:1978;350-354.
12. Silke B., Verma S.P., Frais A., Reynolds G., Taylor S.H. Differential effects of atenolol and celiprolol on cardiac performance in ischemic heart disease. J Cardiovasc Pharm. 8:(suppl 4):1986;S138-S144.
13. El-Tamimi H, Mansour M, Wargovich TJ, Kerensky RA, Chen HJ, Handberg E, Pepine CJ. Intravenous metoprolol enhances coronary vasoreactive response to acetylcholine in patients with chronic stable angina. Circulation 1993;88(suppl I):I-493.
14. Gardiner G.A., Meyerovitz M.F., Boxt L.M., Harrington D.P., Taus R.H., Kandarpa K., Ganz P., Selwyn A.P. Selective coronary angiography using a power injector. Am J Roentgenol. 143:1986;831-833.
15. Zeiher A.M., Drexler H., Wollschläger H., Just H. Endothelial dysfunction of the coronary vasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 84:1991;1984-1992.
16. Quyyumi A.A., Dakak N., Diodati J.G., Gilligan D.M., Panza J.A., Cannon R.O. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 30:1997;1220-1227.
17. Nishida M, Luo XX, Akamatsu Y, Aoki K, Igarashi J, Kuzuya T, Tada M. Nipradilol, a β-adrenergic receptor antagonist containing a nitroxy residue, releases NO in smooth muscle cells via binding to β-receptors. Circulation 1998;98(suppl I):I-404.
18. Cockroft J.R., Chonwienczyk P.J., Brett S.E., Chen C.P.H., Dupont A.G., Van Nueten L., Woodling S.J., Ritter J.M. Nebivolol vasodilates human forearm vasculature evidence for an L-arginine/NO-dependent mechanism . J Pharmacol Exp Therap. 274:1995;1067-1071.
19. Mehta J.L., Lopez L.M., Chen L., Cox O.E. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol. 74:1994;901-905.
20. Pittner H. Hämodynamische Wirkungen von Celiprolol und anderen β-Rezeptoren-Blockern an narkotisierten Hunden. Drug Res. 33:1983;26-29.
21. Mancia G., Grassi G., Parati G., Pomidossi G., Sabadini E., Giannattasio C., Bolla G., Zanchetti A. Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension. J Cardiovasc Pharmacol. 8:(suppl 4):1986;S67-S74.
22. 2) beta-adrenergic blockade on systemic and coronary hemodynamic findings in angina pectoris. Am J Cardiol. 60:1987;244-248.
23. Sievert H., Frey G., Schräder R., Schmidt T., van der Does R., Kaltenbach M., Kober G. Influence of carvedilol and propranolol on coronary blood flow. Eur J Clin Pharmacol. 38:1990;S122-S144.
24. Kern M.J., Petru M.A., Ferry D.R., Eilen S.D., Barr W.K., Porter C.B., O'Rourke R.A. Regional coronary vasoconstriction after combined beta-adrenergic and calcium channel blockade in patients with coronary artery disease. J Am Coll Cardiol. 5:1985;1438-1450.
25. Kaltenbach M. Medikamentöse Therapie der Angina Pectoris. Prüfung verschiedener Medikamente mit Hilfe von Arbeitsversuchen. Drug Res. 20:1970;1304-1310.
26. Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990;81:1255-1235.
27. Jost S., Hausmann D., Lippolt P., Sturm M. Acute effects of celiprolol on angiographically normal and stenotic coronary arteries. Cardiovasc Drugs Ther. 11:1997;133-138.
28. Fleischhauer F.J., Yan W.D., Fischell T.A. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 21:1993;982-989.
29. Mancini G.B.J., Henry G.C., Macaya C., O'Neill B.J., Pucillo A.L., Carere R.G., Wargovich T.J., Mudra H., Lüscher T.F., Klibaner M.I., Haber H.E., Uprichard A.C.G., Pepine C.J., Pitt B. Angiotensin-converting enzyme inhibition with quinalapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 94:1996;258-265.